On the contrary, Wang et al. [21] demonstrated a significantly worse PFS (but not OS) for patients with NPM1-mutated AML harbouring additional MDS-related gene mutations, although patients with concurrent FLT3-ITD mutation exhibited comparable PFS and OS to those with MDS-related gene mutations. This evidence concerns the gene NPM1 and acute myeloid leukemia.